Emma Doud

Dr. Emma Doud

orcid
Associate Director of the Center for Proteome Analysis, IU S...

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2022 in Science Advances
Verified
Journal Article
Open access
BKBrijesh Kumar
Brijesh Kumar
AAAdedeji Adebayo
Adedeji Adebayo
MPMayuri Prasad
Mayuri Prasad
MCMaegan L. Capitano
Maegan L. Capitano
RWRuizhong Wang
Ruizhong Wang
HNHarikrishna Nakshatri
Harikrishna Nakshatri
Tumor tissue collection and processing under physioxia allow highly relevant detection of signaling networks and drug sensitivity.

1 January 2020 in mAbs
Verified
Journal Article
Open access
ZSZaneer Segu
Zaneer Segu
TSTodd Stone
Todd Stone
CBClaudia Berdugo
Claudia Berdugo
ARAnthony Roberts
Anthony Roberts
EDEmma Doud
Emma Doud
YLYunsong Li
Yunsong Li
Glycosylation is a common post-translational modification and critical quality attribute that can modulate the efficacy of therapeutic proteins. In the production of monoclonal antibodies (mAbs), quantifying the glycoform profile is a vital characterization step. Traditional glycan analysis is time consuming and involves steps at extreme temperature or pH, which may alter glycans. Here, we describe a rapid method for glycan analysis in which glycans are released from mAb samples that are bound to protein A columns. Since host cell proteins, which may also contain glycans, were already removed, this step enables analysis of cell culture products. Glycans released from the mAb samples are then derivatized with InstantPC™ labeling agent and analyzed by HILIC-FLD-MS. To illustrate the method, the glycan profiles of six trastuzumab (Herceptin®) antibody lots and four biosimilar developmental lots were analyzed. The results derived from our novel method, which takes less than 90 min, are compared with those from a typical glycan preparation approach.

3 September 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SHSegewkal Hawaze Heruye
Segewkal Hawaze Heruye
JMJered Myslinski
Jered Myslinski
CZChao Zeng
Chao Zeng
AZAmy Zollman
Amy Zollman
SMShinichi Makino
Shinichi Makino
THTakashi Hato
Takashi Hato
The progression of kidney disease varies among individuals, but a general methodology to quantify disease timelines is lacking. Particularly challenging is the task of determining the potential for recovery from acute kidney injury following various insults. Here, we report that quantitation of post-transcriptional adenosine-to-inosine (A-to-I) RNA editing offers a distinct genome-wide signature, enabling the delineation of disease trajectories in the kidney. A well-defined murine model of endotoxemia permitted the identification of the origin and extent of A-to-I editing, along with temporally discrete signatures of double-stranded RNA stress and adenosine deaminase isoform switching. We found that A-to-I editing of antizyme inhibitor 1 (AZIN1), a positive regulator of polyamine biosynthesis, serves as a particularly useful temporal landmark during endotoxemia. Our data indicate that AZIN1 A-to-I editing, triggered by preceding inflammation, primes the kidney and activates endogenous recovery mechanisms. By comparing genetically modified human cell lines and mice locked in either A-to-I–edited or uneditable states, we uncovered that AZIN1 A-to-I editing not only enhances polyamine biosynthesis but also engages glycolysis and nicotinamide biosynthesis to drive the recovery phenotype. Our findings implicate that quantifying AZIN1 A-to-I editing could potentially identify individuals who have transitioned to an endogenous recovery phase. This phase would reflect their past inflammation and indicate their potential for future recovery.

20 June 2025 in Nucleic Acids Research
Verified
Journal Article
Open access
CSCaitlin Specht
Caitlin Specht
ATAlejandro Tapia
Alejandro Tapia
SPSarah Penrod
Sarah Penrod
GSGabriela A Soriano
Gabriela A Soriano
AAAya Awawdeh
Aya Awawdeh
JTJeffery M Tharp
Jeffery M Tharp
Nonsense mutations that introduce premature termination codons (PTCs) into protein-coding genes are responsible for numerous genetic diseases; however, there are currently no effective treatment options for individuals affected by these mutations. One approach to combat nonsense-related diseases relies on the use of engineered suppressor transfer RNAs (sup-tRNAs) that facilitate translational stop codon readthrough, thereby restoring full-length protein synthesis. While several sup-tRNAs have shown promising results in preclinical models, many exhibit low PTC suppression efficiency, precluding their use as therapeutics. For example, glutamic acid (Glu) codons represent one of the most common sites for nonsense mutations, yet existing sup-tRNAs are ineffective at suppressing Glu-to-Stop mutations. To address this limitation, here we describe a rationally designed sup-tRNA (tRNAGluV13) with greatly improved ability to suppress PTCs occurring at Glu codons. We demonstrate that tRNAGluV13 efficiently restores protein synthesis from multiple nonsense-containing reporter genes, faithfully installing Glu in response to PTCs. Additionally, we demonstrate that tRNAGluV13 can functionally rescue pathogenic PTCs that cause hereditary breast and ovarian cancer syndrome and cystic fibrosis. The ability of tRNAGluV13 to effectively suppress one of the most common PTC mutations should greatly expand the potential of sup-tRNA-based therapeutics.

8 April 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ANAzuma Nanamatsu
Azuma Nanamatsu
GRGeorge J. Rhodes
George J. Rhodes
KLKaice LaFavers
Kaice LaFavers
RMRadmila Micanovic
Radmila Micanovic
VLVirginie Lazar
Virginie Lazar
TETarek M. El-Achkar
Tarek M. El-Achkar
In the kidney, cells of thick ascending limb of the loop of Henle (TAL) are resistant to ischemic injury, despite high energy demands. This adaptive metabolic response is not fully understood even though the integrity of TAL cells is essential for recovery from acute kidney injury (AKI). TAL cells uniquely express uromodulin, the most abundant protein secreted in healthy urine. Here, we demonstrate that alternative splicing generates a conserved intracellular isoform of uromodulin, which contributes to metabolic adaptation of TAL cells. This splice variant was induced by oxidative stress and was upregulated by AKI that is associated with recovery, but not by severe AKI and chronic kidney disease (CKD). This intracellular variant was targeted to the mitochondria, increased NAD + and ATP levels, and protected TAL cells from hypoxic injury. Augmentation of this variant using antisense oligonucleotides after severe AKI improved the course of injury. These findings underscore an important role of condition-specific alternative splicing in adaptive energy metabolism to hypoxic stress. Enhancing this protective splice variant in TAL cells could become a therapeutic intervention for AKI.

1 January 2023 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
EDEmma Doud
Emma Doud
EYElizabeth S. Yeh
Elizabeth S. Yeh
Glycosylation has a clear role in cancer initiation and progression, with numerous studies identifying distinct glycan features or specific glycoproteoforms associated with cancer. Common findings include that aggressive cancers tend to have higher expression levels of enzymes that regulate glycosylation as well as glycoproteins with greater levels of complexity, increased branching, and enhanced chain length1. Research in cancer glycoproteomics over the last 50-plus years has mainly focused on technology development used to observe global changes in glycosylation. Efforts have also been made to connect glycans to their protein carriers as well as to delineate the role of these modifications in intracellular signaling and subsequent cell function. This review discusses currently available techniques utilizing mass spectrometry-based technologies used to study glycosylation and highlights areas for future advancement.